e-Article
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Document Type
article
Author
Sue Ann Costa Clemens; Pedro M. Folegatti; Katherine R. W. Emary; Lily Yin Weckx; Jeremy Ratcliff; Sagida Bibi; Ana Verena De Almeida Mendes; Eveline Pipolo Milan; Ana Pittella; Alexandre V. Schwarzbold; Eduardo Sprinz; Parvinder K. Aley; David Bonsall; Christophe Fraser; Michelle Fuskova; Sarah C. Gilbert; Daniel Jenkin; Sarah Kelly; Simon Kerridge; Teresa Lambe; Natalie G. Marchevsky; Yama F. Mujadidi; Emma Plested; Maheshi N. Ramasamy; Peter Simmonds; Tanya Golubchik; Merryn Voysey; Andrew J. Pollard; the AMPHEUS Project; Oxford COVID Vaccine Trial Team
Source
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2) and other variants.